What are the treatment options for non‑small cell lung cancer (NSCLC) based on disease stage and molecular alterations?

NSCLC Treatment Recommendations

Treatment for NSCLC is fundamentally determined by disease stage and molecular/biomarker status, with molecular testing being mandatory before initiating therapy in most cases.

Stage-Based Treatment Algorithm

Early Stage Disease (Stage IB-IIIA)

Surgical resection followed by adjuvant targeted therapy for driver mutations is the standard approach 1, 2.

• EGFR-mutated NSCLC (exon 19 deletion or L858R): Osimertinib 80 mg daily for 3 years after complete resection significantly improves disease-free survival 1, 3
• ALK-positive NSCLC: Alectinib is approved for adjuvant treatment after complete resection 3
• No driver mutations: Consider adjuvant chemotherapy ± immunotherapy based on stage

Critical molecular testing requirement: Test all stage IB-IIIA NSCLC for EGFR mutations and ALK rearrangements to guide adjuvant therapy decisions 1.

Unresectable Stage II/III Disease

After definitive concurrent chemoradiation without progression, consolidation therapy is mandatory 1:

• EGFR exon 19 deletion or L858R mutation: Osimertinib 80 mg once daily until progression (Category 1 for stage III; Category 2A for stage II) 1

  • Median PFS: 39.1 months vs 5.6 months with placebo
  • Reduces new brain metastases: 8% vs 29% with placebo

• No EGFR exon 19 deletion or L858R mutation: Durvalumab 10 mg/kg IV every 2 weeks or 1500 mg every 4 weeks for up to 12 months (Category 1 for stage III; Category 2A for stage II) 1

  • Contraindications: Active autoimmune disease, current immunosuppressive agents
  • Avoid in: ALK, RET, or ROS1 rearrangements (reduced benefit from PD-1/PD-L1 inhibitors)

Critical pitfall: Do not administer TKIs in close temporal proximity to immunotherapy in EGFR-mutated tumors due to increased toxicity risk 1.

Stage IV/Metastatic Disease

Treatment is dictated by molecular alterations identified through comprehensive next-generation sequencing 2, 4.

EGFR-Mutated NSCLC (First-Line)

Two evidence-based options exist 2:

1. Osimertinib with platinum doublet chemotherapy (Moderate evidence, weak recommendation)
2. Amivantamab plus lazertinib (Moderate evidence, weak recommendation)

The RAMOSE trial demonstrated osimertinib plus ramucirumab improved median PFS to 24.8 months vs 15.6 months with osimertinib alone (HR 0.55, P=0.023), though with increased grade ≥3 adverse events (53% vs 41%) 2. This represents a lower-toxicity alternative to combination approaches.

Other Actionable Driver Mutations (Stage IV)

FDA-approved targeted therapies by alteration 5, 6, 4:

• ALK rearrangements: ALK inhibitors (alectinib, brigatinib, lorlatinib)
• ROS1 fusions: ROS1 inhibitors (crizotinib, entrectinib)
• BRAF V600E: BRAF inhibitors (dabrafenib + trametinib)
• KRAS G12C (~15% of NSCLC): Sotorasib or adagrasib after prior chemotherapy/immunotherapy; adagrasib + pembrolizumab shows benefit in first-line with high PD-L1 expression 5
• EGFR exon 20 insertions: Amivantamab after platinum-based chemotherapy 5
• HER2 insertions (2%): Trastuzumab deruxtecan after platinum-based chemotherapy 5
• MET exon 14 skipping (3%): Capmatinib or tepotinib 5
• RET fusions: RET inhibitors (selpercatinib, pralsetinib)
• NTRK fusions: TRK inhibitors (larotrectinib, entrectinib)

No Actionable Mutations (Stage IV)

Immunotherapy-based regimens are standard 7, 6:

• PD-1/PD-L1 inhibitors alone (high PD-L1 expression ≥50%)
• PD-1/PD-L1 inhibitors + platinum doublet chemotherapy
• PD-1/PD-L1 + CTLA-4 inhibitors ± chemotherapy

Essential Molecular Testing Strategy

Comprehensive next-generation sequencing panels are the diagnostic gold standard 3, 5:

• Mandatory testing: EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, HER2, PD-L1 expression
• Timing: At diagnosis for all non-squamous NSCLC and select squamous cases
• Tissue requirement: Adequate biopsy specimen; consider liquid biopsy if tissue insufficient

Key Clinical Pitfalls

1. Never delay molecular testing - initiate reflex testing immediately at diagnosis 5
2. Avoid immunotherapy in untested patients - oncogenic drivers (EGFR, ALK, RET, ROS1) show reduced benefit from checkpoint inhibitors 1
3. Sequential vs concurrent therapy timing - TKI/immunotherapy proximity increases toxicity in EGFR-mutated disease 1
4. Resistance mechanisms - acquired resistance to targeted therapies remains a significant challenge; repeat molecular testing at progression 6